IN8BIO Inc. has released a presentation detailing its ongoing research and development efforts, with a focus on harnessing the power of Gamma-Delta T cells. The presentation highlights the progress and scope of clinical trials for its product candidates, including INB-100, INB-200, INB-400, and INB-600. IN8BIO is also exploring opportunities for certain programs and preclinical assets, supported by the potential to receive additional capital from convertible securities. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.